摘要
目的探讨替吉奥联合奥沙利铂化疗方案对老年胃癌患者临床疗效、毒副反应及肿瘤内分泌指标的影响。方法选取2013年6月至2016年5月我院收治的82例老年胃癌患者为研究对象,按随机数表法分为观察组和对照组,每组41例。对照组采用5-氟尿嘧啶(5-FU)+奥沙利铂+亚叶酸钙方案治疗,每21 d为一个疗程,共治疗3个疗程;观察组采用替吉奥+奥沙利铂方案治疗,每21 d为一个疗程,共治疗3个疗程。3个疗程治疗结束后比较两组患者的临床疗效、毒副反应及治疗前、后肿瘤内分泌指标。结果观察组患者的治疗总有效率为53.66%,明显高于对照组的31.71%,差异有统计学意义(P<0.05);观察组和对照组患者治疗期间白细胞减少Ⅰ、Ⅱ度发生率(34.15%vs 60.98%、7.32%vs 24.39%)、中性粒细胞减少Ⅰ、Ⅱ度发生率(26.83%vs 48.79%、4.88%vs 24.39%)、恶心呕吐Ⅰ、Ⅱ度发生率(46.34%vs 73.17%、2.44%vs 19.51)比较,观察组均低于对照组,差异均有统计学意义(P<0.05);观察组患者治疗前的肿瘤内分泌指标VEGFA、VEGFC、s VEGFR-1水平分别为(209.86±89.47)ng/L、(90.23±19.28)ng/L、(214.37±45.86)ng/L,分别与对照组的(203.15±82.66)ng/L、(87.26±21.35)ng/L、(217.53±49.81)ng/L比较,差异均无统计学意义(P>0.05);观察组患者治疗后的肿瘤内分泌指标VEGFA、VEGFC、s VEGFR-1水平分别为(103.88±68.51)ng/L、(38.16±10.57)ng/L、(537.48±61.32)ng/L,均低于对照组的(165.53±75.42)ng/L、(47.48±11.96)ng/L、(493.64±67.59)ng/L,差异均有统计学意义(P>0.05)。结论替吉奥联合奥沙利铂化疗能有效提高老年胃癌患者的临床疗效,并减轻毒副反应和改善肿瘤内分泌功能。
Objective To investigate the effect of tegafur combined with oxaliplatin, toxic side effects and tu- mor endocrine indexes in elderly patients with gastric cancer. Method A total of 82 elderly patients with gastric cancer were enrolled in our hospital from June 2013 to May 2016. The patients were divided into observation group （n=41） and control group （n=41） according to the random number table. The control group was treated with 5-fluorouracil （5-FU）＋ oxaliplatin＋leucovorin regimen, every 21 d as one course, for 3 courses of treatment. The observation group was treated with tiggio＋oxaliplatin, every 21 d as one course, for 3 courses of treatment. After 3 courses of treatment, the clinical ef- ficacy, toxic side effects and tumor endocrine indexes of the two groups were compared. Results The total effective rate of the observation group was 53.66%, which was significantly higher than 31.71% of the control group （P〈0.05）. During the treatment, the incidence rates of leukopenia Ⅰ,Ⅱ degree （34.15% vs 60.98%, 7.32% vs 24.39%）, neutropenia Ⅰ,Ⅱ degree （26.83% vs 48.79%, 4.88% vs 24.39%）, and nausea and vomiting Ⅰ,Ⅱ degree （46.34% vs 73.17%, 2.44% vs 19.51） in the observation group were significantly lower than those in the control group （P〈0.05）. The expression levels of VEGFA, VEGFC and sVEGFR-1 in the observation group of patients before treatment respectively were （209.86±89.47） ng/L, （90.23±19.28） ng/L, （214.37±45.86） ng/L, respectively, and the levels in the control group were （203.15±82.66） ng/L, （87.26±21.35） ng/L, （217.53±49.81） ng/L. The difference was not significant （P〉0.05）. The expression of VEGFA, VEGFC and sVEGFR-1 in the observation group of patients after treatment respectively were （103.88±68.51） ng/L, （38.16±10.57） ng/L, （537.48±61.32） ng/L, which were lower than （165.53±75.42） ng/L, （47.48± 11.96） ng/L, （493.64±67.59） ng/L in the control group （P〈0.05）. Conclusion Tegafur com
出处
《海南医学》
CAS
2017年第12期1913-1916,共4页
Hainan Medical Journal
基金
新疆维吾尔自治区自然科学基金(编号:2016DOIC136)
关键词
替吉奥
奥沙利铂
老年
胃癌
疗效
毒副反应
内分泌功能
Tegafur
Oxaliplatin
Elderly
Gastric cancer
Efficacy
Toxic side effects
Endocrine function
